Development of platforms to screen drugs targeting mrna translation initiation factors
mRNA translation initiation factors are affected in many diseases, especially multiple cancers. Multiple different studies demonstrate them as targets and biomarkers for cause and progress of the disease. We have developed tools, models and platforms to study them and their role in cancer in response to disease and drug treatments. We can discuss about co-development and collaborative opportunities, if this is a system and mechanism that is of interest to your team and organisation.
About TranslaTale
Translatale Biosystems is a biotechnology company founded in 2022 and headquartered in Bangalore, India. The company focuses on drug discovery by targeting ribosomes and mRNA translation processes. It has developed a platform that integrates experimental techniques and data-driven approaches to screen and identify small molecules capable of modulating mRNA translation. By focusing on these fundamental biological mechanisms, Translatale aims to address unmet medical needs in fields such as oncology, neurodegenerative conditions, and rare diseases.
This technology provides researchers and pharmaceutical partners with tools to evaluate the effects of drugs on protein synthesis, serving as a platform for early-stage drug development. The company works to bridge the gap between preclinical research and clinical applications, utilizing approaches like zebrafish xenografts to create patient avatars for personalized and precision medicine. The company is led by its founders, Gnaneshwar Yadav and Saurabh Mahajan, and has been supported by various incubation programs and grants, including from DBT-BIRAC-BIG and IIMB-NSRCEL, to advance its research and development initiatives.
Inquire about this partnering listing
Looking for
Industry applications
delivered to your inbox.